Saturday, March 4, 2017

SIXTH ANNUAL CONTROVERSIES IN HEMATOLOGIC MALIGNANCIES SYMPOSIUM

HILTON HOTEL-MILWAUKEE, WI

GUEST SPEAKERS

Jeremy S. Abramson, MD, MMSC
Director, Lymphoma Program
Jon and Jo Ann Hagler Chair in Lymphoma
Massachusetts General Hospital Cancer Center
Assistant Professor of Medicine,
Harvard Medical School

Frederick R. Appelbaum, MD
Deputy Director and Executive Vice President,
Fred Hutchinson Cancer Research Center
Executive Director and President,
Seattle Cancer Care Alliance

Noelle Frey, MD, MS
Assistant Professor of Medicine
Associate Director of Bone Marrow Transplant and Cellular Therapy
Hospital of the University of Pennsylvania

FROEDTERT AND THE MEDICAL COLLEGE OF WISCONSIN SPEAKERS

Angela Canadeo, PharmD, BCOP
Clinical Oncology Pharmacist
Malignant Hematology and Blood and Marrow Transplant
Froedtert & The Medical College of Wisconsin

Karen Carlson, MD, PhD
Assistant Professor of Medicine
Division of Hematology & Oncology
Medical College of Wisconsin

Heidi F. Christianson, PhD
Associate Professor, Training Director
Health Psychology Residency Department of Psychiatry and Behavioral Medicine
Medical College of Wisconsin

Jayme Cotter, MS, RN, AOCNS, ACNS-BC
Oncology Clinical Nurse Specialist
Froedtert & the Medical College of Wisconsin

Binod Dhakal, MD, MS
Assistant Professor of Medicine
Division of Hematology & Oncology
Medical College of Wisconsin

Patrick Foy, MD
Assistant Professor of Medicine
Division of Hematology & Oncology
Medical College of Wisconsin

Laura Michaelis, MD
Associate Professor of Medicine
Division of Hematology & Oncology
Medical College of Wisconsin

Nirav N. Shah, MD
Assistant Professor of Medicine
Division of Hematology & Oncology
Medical College of Wisconsin

Purpose:
This one-day symposium will raise and address the most challenging questions in current clinical practice for hematologic malignancy. Topics will include CAR-T cell therapies, AML, CLL, frontline management of DLBCL, and hematological complications facing patients with lymphoma, leukemia and myeloma.

Target Audience:
Physicians, Physician Assistants, Nurse Practitioners, Pharmacists, Registered Nurses

Educational Objectives:
The aim of this conference is to highlight major controversies in the treatment of hematological malignancies. At the completion of this activity, attendees will be able to make therapeutic decisions based on the available data, realizing the ongoing debate in those areas.

Please contact Dan Bullock at hemoncsymposium@mcw.edu with any questions.
AGENDA

7:30-8:20am Registration/Breakfast/View Exhibits
8:20-8:30am Introduction
8:30-9:15am CAR-T Cells in B-cell Malignancies
   Noelle Frey, MD, University of Pennsylvania, Hospital of the University of Pennsylvania
9:15-10:00am Using Molecular Tools to Deliver Precision Care to Patients with
   Myeloid Malignancies
   Karen Carlson, MD, PhD, Medical College of Wisconsin
10:00-10:15am Break
10:15-11:00am Recent Advances in Allogeneic HCT
   Dr. Frederick Appelbaum, University of Washington, Fred Hutchinson Cancer
   Research Center
11:00-11:45am Breakout Sessions
   Hematological Complications for Heme Malignancy Patients: A series of clinical vignettes
   Patrick Foy, MD, Medical College of Wisconsin
   Targeting Chronic Lymphocytic Leukemia: Expanding Our Arsenal with Oral Therapies
   Angela Canadeo, PharmD,BCOP, Froedtert & The Medical College of Wisconsin
   It’s More Than Sadness: The Impact, Identification Strategies, and Management of Depression in Patients with Hematologic Malignancies
   Heidi Christianson, PhD, Medical College of Wisconsin and Froedtert Hospital
   Jayme Cotter, MS, RN, Medical College of Wisconsin
11:45-12:45pm Lunch
12:45-1:30pm R-CHOP: Does One Size Still Fit All in Diffuse Large B-cell Lymphoma?
   Jeremy Abramson, MD, Harvard University, Massachusetts General Hospital
1:30-2:15pm Treatment Options in Relapsed/Refractory Multiple Myeloma
   Binod Dhakal, MD, MS, Medical College of Wisconsin
2:15-3:00pm High Risk CLL: Is Allogeneic Transplant a Consideration in the Era of Targeted Agents?
   Nirav N. Shah, MD, Medical College of Wisconsin
   Laura C. Michaelis, MD, Medical College of Wisconsin
3:00pm Adjourn

ACCOMMODATIONS:
Hilton Hotel - 509 W. Wisconsin Ave. - Milwaukee, WI 53203

A block of rooms has been reserved for the evening of Friday March 3, 2017 at a special rate of $129 (single or double occupancy). The special room rate will be available until the group block is sold out.

Phone Reservations: 414-271-7250
Group Name: Medical College of Wisconsin – Hematology
Group Code: MCWH

Please ask for a complimentary parking ticket available at the registration tables on the 5th floor of the Hilton in the Crystal Ballroom.
REGISTRATION

MD & ALLIED HEALTH PROFESSIONALS ONLY (ONLINE REGISTRATION): If you have not previously created your Ethos CE profile (CME account) through the Medical College of Wisconsin, please go to:
http://ocpe.mcw.edu/hemonc/content/sixth-annual-controversies-hematologic-malignancies-symposium
Click on “Create Account” in the upper right hand corner.

Please scroll to the bottom of the page and click on the “Begin” button to register for the symposium.

PRE-REGISTRATION IS REQUIRED: Please complete the pharmacist registration form and return via email (Mindy.Waggoner@froedtert.com) or fax (414)805-9283 to Mindy Waggoner by Monday, February 27, 2017.

REQUIREMENTS FOR PHARMACY CE CREDIT: Participants who attend this knowledge-based program and complete the evaluation and assessment for each session will receive up to 5.25 continuing education contact hours (0.525 CEUs). Evaluation and assessment materials must be turned in on March 5, 2016 at the end of the symposium in order to receive credit.

Evaluation materials may be accessed at the registration tables onsite.

Breakdown of Pharmacy Credits and Learning Objectives

**CAR T Cell Therapy for CD19+ malignancies**
At the completion of this activity, the participant will be able to:
1. Describe the biology and mechanism of action of CAR T cells
2. Evaluate outcomes of patients with ALL, CLL and B cell NHL treated with CART19
3. Recognize and manage complications of CAR T cell therapy including cytokine release syndrome
(0846-0000-17-007-L01-P)

**Using Molecular Tools to Deliver Precision Care to Patients with Myeloid Malignancies**
At the completion of this activity, the participant will be able to:
1. Identify the benefits and limitations of current testing modalities available for molecular diagnostics in the context of myeloid malignancies
2. Evaluate the timing of molecular testing with respect to trajectory of care for patients with myeloid malignancies
(0846-0000-17-006-L01-P)

**The Grand Challenges of Allogeneic Hematopoietic Cell Transplantation**
At the completion of this activity, the participant will be able to:
1. Describe progress in the broadening of donor availability
2. Review studies attempting to reduce the burden of graft-versus-host disease
3. Describe methods to reduce post-transplant disease recurrence
(0846-0000-17-004-L01-P)

**Targeting Chronic Lymphocytic Leukemia: Expanding Our Arsenal with Oral Therapies**
At the completion of this activity, the participant will be able to:
1. Describe the pathophysiology and microenvironment in chronic lymphocytic leukemia (CLL) and examine therapeutic drug targets
2. Identify common toxicities and appropriate monitoring for patients receiving oral therapy with ibrutinib, idelalisib, and venetoclax
3. Analyze clinical outcomes of patients receiving combination treatment with monoclonal antibodies and oral therapies
4. Identify CLL pipeline drugs
(0846-0000-17-003-L01-P)

**R-CHOP: Does One Size Still Fit All in Diffuse Large B-Cell Lymphoma?**
At the completion of this activity, the participant will be able to:
1. Recognize the biologic and clinical heterogeneity within diffuse large B-cell lymphoma
2. Identify upfront treatment options for diffuse large B-cell lymphoma
(0846-0000-17-002-L01-P)

**Treatment Options in Relapsed/Refractory Multiple Myeloma**
At the completion of this activity, the participant will be able to:
1. Define relapsed/refractory multiple myeloma
2. Identify treatment options for early relapsed/refractory disease
3. Identify treatment options for late relapsed/refractory disease
4. Recognize the role of transplant in relapsed/refractory disease
5. Assess new therapeutic avenues including immunotherapy and cellular therapy
(0846-0000-17-005-L01-P)

**High Risk CLL: Is Allogeneic Transplant a Consideration in the Era of Targeted Agents**
At the completion of this activity, the participant will be able to:
1) Identify novel therapies for relapsed, refractory CLL
2) Review the role of allogeneic transplant in CLL as a treatment modality in 2017
(0846-0000-17-008-L01-P)

In addition to our exhibitors, we would like to thank our Premier Exhibitors for supporting this program:

Support from the Schroeder Fellowship in Clinical Oncology at Aurora St. Luke’s Medical Center.
Saturday, March 4, 2017

Sixth Annual Controversies in Hematologic Malignancies Symposium

Hilton Hotel-Milwaukee, WI